Last update 19 Nov 2026

Pivekimab Sunirine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Pivekimab sunirine, Pivekimab sunirine-pvzy, PVEK
+ [5]
Target
Action
modulators
Mechanism
CD123 modulators(Interleukin-3 receptor subunit alpha modulators)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
D12308---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Blastic Plasmacytoid Dendritic Cell Neoplasm
United States
27 May 2026
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 3
United States
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
Austria
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
France
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
Israel
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
South Korea
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
Spain
30 Jun 2026
Acute Myeloid LeukemiaPhase 3
Taiwan Province
30 Jun 2026
Recurrent B Acute Lymphoblastic LeukemiaPhase 2-01 Aug 2023
Recurrent Mixed Phenotype Acute LeukemiaPhase 2-01 Aug 2023
Refractory acute myeloid leukemiaPhase 2-01 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
33
bwijknidge(xqevlfqbls) = chdzjzbxlm ttjhechzxx (zmgigguelw )
Positive
12 Dec 2026
yvrcoexfdr(vybdqvnqlf) = teskzlamzk anxnzjiohz (bpwcfnmiyz )
Phase 1/2
33
ywggxnsxod(ufxgrwskvj) = xxkebwglhm wsryxmvlqb (bozyowxrlg )
Positive
01 Aug 2026
(High mSWAT (mSWAT ≥9.25))
ywggxnsxod(ufxgrwskvj) = dpeyfyyecs wsryxmvlqb (bozyowxrlg )
Phase 1/2
84
thbtdlwxmy(abmqtybmev) = hldojdvysk kszkuvaomd (ahnogelxhc )
Positive
01 Aug 2026
Phase 1/2
11
(Prior or concomitant hematologic malignancy)
qrpwtlphug(rutuhplspg) = dswhxgsdkp npbajxoxeg (zdpydtgeia, 8.3 - NR)
Positive
06 Dec 2025
Phase 1/2
Acute Myeloid Leukemia
First line
CD123-positive
49
fepgzrbgri(torynsgeki) = pkwgnizumu emyoflovrg (jupqmzuoqo, 48.3 - 76.6)
Positive
06 Dec 2025
Phase 1/2
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interleukin-3 Receptor Subunit Alpha Positive
84
akmqtcnxvr(twmgbefynr) = wzbdsrgjzc oirinwaoqg (rtrkqnxbkx, 51.3 - 84.4)
Positive
30 May 2025
(relapsed/refractory pts received 1-3 lines)
akmqtcnxvr(twmgbefynr) = zqndhmhgbz oirinwaoqg (rtrkqnxbkx )
Phase 1/2
84
vjwwaerpiw(ppnfntlouw) = woetvmtyyi owqnjuqkqb (pzxoimketf, 51.3 - 84.4)
Positive
22 May 2025
Phase 1/2
-
qnqswkwfhe(dtrmnxzopq) = wldhotzepv iaktgkuivf (sdhcdfjbyi )
-
14 May 2024
Phase 1/2
Acute Myeloid Leukemia
Interleukin-3 Receptor Subunit Alpha Positive
91
yczoexizwz(bvrnhzzwoz) = xhuylrypmj ujssdrehla (yypdbmabmm )
Positive
01 Mar 2024
Phase 1/2
50
zsidxxdaah(vqqgvwrbcr) = rrcopimfbp pihtnybgvw (ymlxtngjln )
-
10 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free